Natera, Inc. announced that it has finished enrolling patients in the ACES‑EMB randomized controlled trial, the first study designed to compare its Prospera heart test with routine endomyocardial biopsy monitoring in heart‑transplant recipients. The trial enrolled more than 300 patients across 17 U.S. transplant centers and will follow participants for 12 months to determine whether Prospera can safely replace invasive biopsies for rejection surveillance.
The ACES‑EMB design randomizes patients one month after transplant and tracks outcomes for a full year. By enrolling 300+ patients, the study provides the largest evidence base to date for donor‑derived cell‑free DNA (dd‑cfDNA) as a non‑invasive biomarker of acute rejection. If Prospera demonstrates non‑inferiority to biopsy, it could become the new standard of care, reducing procedural risk and cost for the roughly 4,500 heart transplants performed annually in the United States.
Natera’s recent financial performance underscores the strategic importance of this milestone. The company reported fourth‑quarter 2025 revenue of $660 million, up 39% YoY, and full‑year 2025 revenue of $2.3 billion, a 35% increase from 2024. Signatera, the oncology dd‑cfDNA test, remains the primary revenue driver, while the organ‑health segment, which includes Prospera, is expanding rapidly. The company’s stock has risen 74% over the past six months, reflecting investor confidence in its growth trajectory.
Dr. Palak Shah, principal investigator for ACES‑EMB, said, “This trial could fundamentally change the way we care for our patients, demonstrating the potential of dd‑cfDNA testing as the surveillance modality of choice after transplant.” Chief medical officer of organ health, Dr. Sangeeta Bhorade, added, “Enrollment completion is an important milestone toward generating the level of evidence needed to inform changes in heart transplantation.”
Analysts and investors have reacted positively to the enrollment news. Consensus “Buy” ratings from 14 analysts and a 36% “Strong Buy” share of the rating base reflect confidence in Natera’s clinical pipeline. Insider selling by CEO Steven Chapman and co‑founder Sheena Jonathan was limited to tax‑related transactions and is not viewed as a negative signal. The market has noted the company’s strong revenue growth and the potential for Prospera to capture a sizable share of the heart‑transplant monitoring market.
The trial’s completion positions Natera to pursue reimbursement expansion for Prospera, potentially unlocking a new revenue stream in a market of 4,500 annual heart transplants. A successful trial could shift the industry away from invasive biopsies, reduce complications, and lower overall care costs, giving Natera a competitive edge over traditional monitoring methods and strengthening its organ‑health portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.